Allogene Therapeutics Inc Dossier - Source-backed chat

Allogene Therapeutics Inc

ALLONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.64

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.60Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $552.8M

Enterprise Value $514.2M

Shares Outstanding 345.5M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Allogene Therapeutics is a pioneer in the development of off-the-shelf, allogeneic CAR-T cell therapies. The company's investment thesis has been significantly de-risked by positive interim futility data from its pivotal Phase 2 ALPHA3 trial of cema-cel in large B-cell lymphoma (LBCL), which demonstrated a 58.3% MRD clearance rate compared to 16.7% in the observation arm. Furthermore, a successful $200.4 million public offering in April 2026 has extended the company's cash runway into the first quarter of 2029, providing ample financial flexibility to achieve major clinical milestones. With a planned leadership transition to Dr. Zachary Roberts (effective July 1, 2026) ensuring clinical continuity, Allogene is well-positioned to validate its scalable, off-the-shelf platform across both oncology and autoimmune diseases.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$9.00

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.8515%

The bear case is triggered if the ALPHA3 trial fails to show a statistically significant EFS benefit over observation in the primary analysis, or if safety concerns (such as severe infections or neurotoxicity) emerge in larger patient cohorts. Additionally, if the ALLO-329 program fails to show sufficient CAR-T persistence or clinical efficacy in autoimmune diseases, the platform's valuation would be severely impaired, forcing the company to seek dilutive financing or strategic alternatives.

Base CaseCentral scenario

$8.3560%

The base case assumes cema-cel continues to show strong efficacy and safety in the ALPHA3 trial, meeting its primary EFS endpoint in 2028 and achieving regulatory approval in late 2028 or 2029. The ALLO-329 program delivers promising proof-of-concept data, establishing a clear development path in autoimmune diseases. The company's cash runway remains secure into early 2029, minimizing near-term dilution risks.

Bull CaseUpside scenario

$14.0025%

The bull case assumes rapid enrollment and outstanding Event-Free Survival (EFS) data in the ALPHA3 trial, leading to an accelerated FDA approval of cema-cel by 2028 as a first-line consolidation therapy, capturing a significant share of a $5 billion market. Additionally, the ALLO-329 program successfully validates the Dagger platform, demonstrating robust efficacy in autoimmune diseases without the need for harsh chemotherapy preconditioning, opening up a massive new therapeutic market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pivotal Phase 2 ALPHA3 trial demonstrated a highly encouraging 58.3% MRD clearance rate for cema-cel versus 16.7% for observation, with a clean safety profile supporting outpatient administration.
Strong balance sheet with cash runway extended into Q1 2029 following a $200.4 million public offering in April 2026, reducing near-term financing risk.
Expansion of the off-the-shelf CAR-T platform into autoimmune diseases via the ALLO-329 program, leveraging the proprietary Dagger technology to reduce or eliminate chemotherapy-based lymphodepletion.
Seamless leadership transition with Chief Medical Officer Dr. Zachary Roberts, who designed and executed the ALPHA3 trial, stepping up as CEO effective July 1, 2026.

Key Investment Risks

Clinical trial execution risks, particularly the long-term Event-Free Survival (EFS) primary endpoint for the ALPHA3 trial, which is not expected to yield primary analysis results until mid-2028.
Intense competition from approved autologous CAR-T therapies (e.g., Yescarta, Breyanzi) and emerging in vivo CAR-T platforms.
Potential safety risks associated with lymphodepletion regimens, as highlighted by a historical patient death in 2025 related to the experimental lymphodepletion drug ALLO-647 (subsequently discontinued).
Pre-revenue status and high operational cash burn, with 2026 operating cash expense guided at $150 million to $165 million.

Thesis Invalidation Triggers

Failure of the ALPHA3 trial to meet its primary Event-Free Survival (EFS) endpoint in the primary analysis.
Inability of ALLO-329 to demonstrate clinical efficacy or CAR-T persistence in the Phase 1 RESOLUTION trial.
Emergence of severe, treatment-related adverse events (such as severe CRS, ICANS, or GvHD) that compromise the outpatient feasibility of cema-cel.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.